• Eovist®

An Essential Diagnostic Tool to Support Your Magnetic Resonance (MR) Liver Imaging Practice

Eovist® is the only FDA-approved Hepatobiliary Specific Contrast Agent (HBA) for MR imaging of the liver.1,2 It is a bi-phasic contrast agent combining dynamic phase imaging (similar to extracellular agents) along with functional, hepatobiliary phase information to support your comprehensive evaluation of focal liver disease.2

Eovist® is indicated for intravenous use in magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in patients with known or suspected focal liver disease.

In addition to dynamic-phase imaging, Eovist® specifically targets functioning hepatocytes within the liver providing additional morphological and functional images about lesion cell composition.1,2

How Eovist®, a hepatobiliary agent, works2

  • Following Injection, Eovist® is equally eliminated through the renal and hepatic systems
  • Eovist® is initially distributed in the extracellular space, allowing for arterial, portal venous, and transitional imaging phase1,3
  • Further assessment of lesions through hepatobiliary phase imaging at 20 minutes post injection:
    •  Lesions with little or no hepatobiliary function will generally not accumulate Eovist® 
    • Lesions with normal hepatobiliary function will accumulate Eovist®

References: 1. Eovist® [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2018. 2. Seale MK, Catalano OA, Saini S, Hahn PF, Sahani DV. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree. Radiographics. 2009;29:1725-1748. doi: 10.1148/rg.296095515. 3. American College of Radiology CT/MRI Li-RADS 2018 CORE.

In clinical trials among 1,989 patients, of whom 1,581 received the recommended dose:

  • Overall, 4% of subjects reported one or more reactions during a follow-up period that for most subjects extended 24 hours after Eovist® administration. The adverse reactions were predominantly of mild to moderate severity.
  • The most frequent (≥0.5%) adverse reactions associated with the use of Eovist® were nausea, headache, feeling hot, dizziness, and back pain.

Eovist_Adverse Reactions_Table 1@2x

Dosing Eovist®

  • Due to high relaxivity in plasma and the liver, the approved dose of Eovist® injection is 0.025 mmol/kg.1



The Eovist® 15 mL single-dose vial is available to conveniently dose patients weighing 220 lbs to 330 lbs.

  • Quality: Maintain image quality through appropriate weight-based dosing in patients requiring >10 mL
  • Minimization of waste: Use one 15 mL vial instead of two 10 mL vials

Dosing Chart

Dynamic and functional liver imaging in <30 minutes1

Eovist® MRIs don’t have to require extended table time. Imaging protocols with Eovist® allow for the collection of dynamic and functional information in under 30 minutes1, that is important to your department and patient scheduling needs.



References: 1. Eovist® [package insert]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; 2018. 2. American College of Radiology CT/MRI Li-RADS 2018 CORE. 3. Jhaveri K, Cleary S, Pascale A. Consensus Statements From a Multidisciplinary Expert Panel on the Utilization and Application of a Liver-Specific MRI Contrast Agent (Gadoxetic Acid). Am J Roentgen AJR. 2015;204:498-509. 4. Yoshioka H, Takahashi N, Yamaguchi M. Double Arterial Phase Dynamic MRI with Sensitivity Encoding (SENSE) for Hypervascular Hepatocellular Carcinomas. J Magn Reson Imaging. 2002;16:259-266.

See Eovist in action with the case studies below. Or go to the Resources section to see all videos.

57-year-old male with suspected liver metastasis from renal cell carcinoma 

59‐year‐old female with history of Hepatitis C 

52-year-old male with suspected liver metastasis from colorectal cancer

Eovist® Packaging

  •  Eovist® injection is supplied in single-dose, rubber-stoppered vials containing 181.43 mg/mL of gadoxetate disodium, equivalent to 0.25 mmol/mL
  • The recommended dose of Eovist® injection is 0.025 mmol/kg body weight